Zacks Investment Research lowered shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) from a hold rating to a sell rating in a report issued on Tuesday, July 11th.

According to Zacks, “AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician’s office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. “

Separately, Stifel Nicolaus decreased their price objective on shares of AcelRx Pharmaceuticals from $15.00 to $14.00 and set a hold rating for the company in a research note on Tuesday, March 14th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. The company has a consensus rating of Hold and a consensus price target of $7.57.

AcelRx Pharmaceuticals (ACRX) traded up 1.72% during midday trading on Tuesday, hitting $2.95. The company had a trading volume of 852,258 shares. The stock’s 50-day moving average price is $2.65 and its 200-day moving average price is $2.77. The stock’s market cap is $133.87 million. AcelRx Pharmaceuticals has a 52-week low of $1.95 and a 52-week high of $4.08.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings data on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.01. AcelRx Pharmaceuticals had a negative return on equity of 478.66% and a negative net margin of 319.19%. The firm had revenue of $2.66 million during the quarter, compared to analyst estimates of $2.63 million. On average, equities research analysts expect that AcelRx Pharmaceuticals will post ($1.19) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/08/07/zacks-investment-research-downgrades-acelrx-pharmaceuticals-inc-acrx-to-sell-updated-updated-updated.html.

In other news, major shareholder Life Sciences Maste Perceptive sold 875,000 shares of the firm’s stock in a transaction on Monday, June 19th. The shares were sold at an average price of $2.40, for a total transaction of $2,100,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 28.10% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in ACRX. ING Groep NV increased its position in shares of AcelRx Pharmaceuticals by 200.0% in the first quarter. ING Groep NV now owns 39,000 shares of the specialty pharmaceutical company’s stock valued at $123,000 after buying an additional 26,000 shares during the period. Acadian Asset Management LLC increased its position in shares of AcelRx Pharmaceuticals by 326.1% in the first quarter. Acadian Asset Management LLC now owns 41,927 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 32,087 shares during the period. Teachers Advisors LLC increased its position in shares of AcelRx Pharmaceuticals by 14.6% in the fourth quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 8,475 shares during the period. Bank of New York Mellon Corp increased its position in shares of AcelRx Pharmaceuticals by 6.6% in the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock valued at $355,000 after buying an additional 6,942 shares during the period. Finally, LMR Partners LLP purchased a new position in shares of AcelRx Pharmaceuticals during the second quarter valued at approximately $319,000. Hedge funds and other institutional investors own 30.39% of the company’s stock.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Stock Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.